NCT01639599View on ClinicalTrials.gov

Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

May 31, 2013

Conditions
Gynecological Disease
Interventions
DRUG

Dexamethasone iv injection

Dexamethasone 5mg iv during anesthesia induction

DRUG

Dexamethasone, haloperidol

dexamethasone + haloperidol 1mg

DRUG

Dexamethasone, haloperidol

Active Comparator: dexamethasone + haloperidol 2mg

All Listed Sponsors
lead

The Catholic University of Korea

OTHER

NCT01639599 - Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients | Biotech Hunter | Biotech Hunter